Skip to search formSkip to main contentSkip to account menu

beclobrate

Known as: 2-(4-((4-chlorophenyl)methyl)phenoxy)-2-methylbutanoic acid ethyl ester, Butanoic acid, 2-(4-((4-chlorophenyl)methyl)phenoxy)-2-methyl-, ethyl ester, (+-)- 
A structural analog of clofibrate, converted to its free acid form after oral administration. Beclobrate reduces LDL-cholesterol and increased HDL… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A mild and efficient method for the synthesis of unsymmetrical diaryl- and triarylmethanes through a B(C6F5)3 catalyzed reduction… 
2011
2011
SummaryBeclobrat is a new fibric acid derivative with potent cholesterol- and triglyceride-lowering effects. Pharmacodynamic and… 
Review
1991
Review
1991
Dyslipidemia of chronic renal failure is of multifactorial origin. Decreased activity of lipoprotein lipase and hepatic… 
1991
1991
1991
1991
The major biotransformation pathway for the chiral lipid-regulating agent beclobrate is conversion to the corresponding… 
1985
1985
The major pathway of biotransformation of beclobrate [(2-[4-[(4-chlorophenyl)methyl]phenoxy]-2-methylbutyric acid ethyl ester] is… 
1983
1983
A new diphenylmethane derivative with potent hypolipidemic activity, ethyl-(+/-)-2-[[alpha-(p-chlorophenyl)-p-tolyl]-oxy]-2… 
1981
1981
First clinical results are presented for two newly developed drugs. Both are diphenylmethane derivatives named ethyl-(+/-)-2…